Drug intelligence / Profile preview

BOD-2

Development stage: Preclinical
Lead developer: Zambon
Administration: Inhalation

Overview

BOD-2 is an early-stage investigational drug candidate being developed by Zambon as part of its 'Breath of Discovery' (BOD) research program. This initiative is focused on identifying and advancing novel therapeutic candidates for the treatment of severe respiratory diseases, with a particular emphasis on inhaled delivery systems. As of 2024, BOD-2 is positioned in the discovery or preclinical phase of Zambon's R&D pipeline. Specific details regarding its biological target, molecular mechanism of action, and precise clinical indication (such as asthma, COPD, or rare lung diseases) have not yet been publicly disclosed by the company.

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on BOD-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOD-2.

Explore the full profile